These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 33059198)
1. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies. Zhou H; Yang M; Cui L; Jiang J Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198 [TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know. Jhaveri KD; Rosner MH Clin J Am Soc Nephrol; 2018 May; 13(5):796-798. PubMed ID: 29523675 [No Abstract] [Full Text] [Related]
3. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Hughes AD; Teachey DT; Diorio C Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374 [TBL] [Abstract][Full Text] [Related]
4. Acute kidney injury following chimeric antigen receptor T-cell therapy: Epidemiology, mechanism and prognosis. Yang Y; Luo K; Xu G Clin Immunol; 2024 Sep; 266():110311. PubMed ID: 38996858 [TBL] [Abstract][Full Text] [Related]
5. Reactions Related to CAR-T Cell Therapy. Miao L; Zhang Z; Ren Z; Li Y Front Immunol; 2021; 12():663201. PubMed ID: 33995389 [TBL] [Abstract][Full Text] [Related]
7. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Major A; Collins J; Craney C; Heitman AK; Bauer E; Zerante E; Stock W; Bishop MR; Jasielec J Leuk Lymphoma; 2021 Jul; 62(7):1765-1769. PubMed ID: 33559517 [No Abstract] [Full Text] [Related]
8. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884 [TBL] [Abstract][Full Text] [Related]
9. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Walton ZE; Frigault MJ; Maus MV Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525 [TBL] [Abstract][Full Text] [Related]
10. CAR T-cell therapy for solid tumours. The Lancet Oncology Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740 [No Abstract] [Full Text] [Related]
11. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K Front Immunol; 2021; 12():611366. PubMed ID: 33708205 [TBL] [Abstract][Full Text] [Related]
12. Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy. Hoyt R; Ye Z; Dasgupta A Clin Chim Acta; 2024 Jun; 559():119704. PubMed ID: 38697457 [TBL] [Abstract][Full Text] [Related]
13. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789 [TBL] [Abstract][Full Text] [Related]
14. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Gupta S; Seethapathy H; Strohbehn IA; Frigault MJ; O'Donnell EK; Jacobson CA; Motwani SS; Parikh SM; Curhan GC; Reynolds KL; Leaf DE; Sise ME Am J Kidney Dis; 2020 Jul; 76(1):63-71. PubMed ID: 31973908 [TBL] [Abstract][Full Text] [Related]
15. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors. Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR Front Immunol; 2021; 12():738456. PubMed ID: 34721401 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Brudno JN; Kochenderfer JN Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964 [TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
18. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Siegler EL; Kenderian SS Front Immunol; 2020; 11():1973. PubMed ID: 32983132 [TBL] [Abstract][Full Text] [Related]
19. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Fischer JW; Bhattarai N Front Immunol; 2021; 12():693016. PubMed ID: 34220853 [TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]